Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16).

In the subgroup with a complete or partial radiologic response to latest ARPI (n = 29), darolutamide achieved a highly significant rPFS prolongation (HR, 0.35 [95% CI, 0.14 to 0.87]; P = .019) and OS (HR, 0.26 [95% CI, 0.06 to 1.19]; P = .063), while in the subgroup with stable or progressive disease as best response to latest ARPI (n = 61), no significant between-arm difference was observed (HR, 0.7 [95% CI, 0.36 to 1.35]; P = .28; HR, 0.97 [95% CI, 0.39 to 2.43]; P = .95; Appendix Fig A 2 , online only).

also in 132,142 other papers